SynBioBeta Speaker
Richard Yu
CEO and co-founder
Abalone Bio
YEAR
25
May 2025, SynBioBeta
Keynote Speaker
Richard's path to co-founding Abalone Bio started at UC Berkeley in Physics, Biophysics, and Computer Science, and wound its way through early efforts at protein secondary structure prediction with Teresa Head-Gordon at UC Berkeley/LBNL, then to protein engineering and structural biology with Axel Brunger at Yale. After receiving his PhD in 2000, he was a member of one of the first systems and synthetic biology interdisciplinary efforts with Roger Brent and Sydney Brenner at the Molecular Sciences Institute, where he met co-founder Gustavo Pesce. Abalone Bio grew out of an "a-ha!" moment that produced a hybrid synthetic biology/computational antibody discovery and creation technology that uniquely draws on their genetics, synthetic biology, quantitative systems biology, and computational experiences to meet a long-standing therapeutic need for safe and effective drugs for undrugged or poorly drugged targets.
SynBioBeta 2025 - Keynote
Next-Gen Medicine: AI-Powered Advances Reshaping Human Therapeutics
Dive into the cutting-edge today, not just the promises of tomorrow. This dynamic breakout session features biotech visionaries actively leveraging machine learning and AI to transform the engineering of human therapeutics. Hear firsthand from industry pioneers pushing the boundaries—from accelerating drug target discovery to streamlining clinical development pipelines. Learn how advanced analytics and big data are already enhancing personalized medicine, boosting clinical success rates, and rapidly reshaping the future landscape of healthcare. Don't miss this inside look at the real-world innovations redefining what's possible in therapeutic discovery and precision medicine.
All Categories
